There is a possibility that many of the hundreds of chemicals that produce allergic contact dermatitis (ACD) in humans might be environmental carcinogens (1) . Most contact sensitizers are electrophiles (2) . They are Table 1 Gavage form on DNA as well as on protein, resulting in genetic damage and the initiation of the carcinogenic process. Genotoxic carcinogens have been shown to be contact sensitizers in the skin of the guinea pig (4) and in the mouse ear (5) . A number of chemicals known to be contact sensitizers for humans (6) are found in the NIH list of carcinogens (7 Feed Abbreviations: SAL, Ames Salmonella mutagenesis assay; CHO, Chinese hamster ovary cell assay for chromosomal abnormalities; CAS, Chemical Abstracts Registry number; CS, contact sensitization. aRFB-primary rationale for the bioassay as follows: 1, widespread use; 2, structural relation with known carcinogen or mutagen; 3, inadequate previous study; 4, representative of a structural class; 5, drug with prolonged exposure; 6, potential use as an antineoplastic drug; 7, preexisting evidence of carcinogenicity; and 8, potential warfare agent. "Tumor score is the number of different organs that showed tumor induction in mice and rats of both sexes; parentheses indicate the number of tumor sites that were obtained only on a single species; se-tumor responses indicate those that were classified as some evidence in contrast to the stronger designation of clear evidence.
response to each chemical in Tables 1-4 was the sum of the number of organs that had statistically significant tumor induction across all four test groups; this is called the tumor score. Thus, if the liver were the only organ with statistically significant tumor induction by a given chemical, and this occurred in male and female rats and mice, the tumor score for that chemical would be 4. If four different organs in female mice were involved in tumor induction and none of the three other groups showed a tumor response, the tumor score for that chemical would also be 4; this illustration is an extreme example of a non-uniform response, which in fact did not occur. The tumor score for each chemical was a measure of the pervasiveness of tumor induction with respect to sex, organ, and species. It was not a measure of potency in the sense of the daily dosage required to induce a given level of tumorigenic response. A zero score, of course, indicated a nontumorigenic response.
The terminology used in the technical reports changed over the years. The earlier reports used the terms positive or suggestive evidence, either of which we considered to be a tumorigenic response. The later reports used the terminology for the tumor bioassays as clear evidence, some evidence, equivocal evidence, or no evidence. We considered either clear or some evidence as an indication of tumorigenicity; the less decisive some evidence responses are indicated in Tables 1-4 . The rationale for doing the bioassay was obtained from each technical report. The primary rationales are as follows: 1) widespread usage; 2) structural resemblance to a known carcinogen or mutagen; 3) an inadequate previous study; 4) representative of a structural class that had not been adequately studied; 5) a drug whose use is prolonged; 6) an antineoplastic drug; 7) preexisting evidence ofcarcinogenicity; and 8) potential use as a warfare agent. The first two rationales included 82% of the chemicals. Table 5 summarizes the data from the entire NTP bioassay sample with respect to genotoxicity, contact sensitization, and tumorigenicity, including the proportion of some evidence tumor responses and the primary rationale for the decision to test the chemical. All of the differences, except where indicated, were statistically significant in a two-tailed test at p = <0.05. There was a total of 209 chemicals in the analysis, including the known contact sensitizers and those that were not known to be such. The majority of the chemicals were SALP, i.e., 122 (58%) compared to 87 (42%) that were SAL-. In both the SAL+ and SAL-groups, the majority of chemicals were CHO+, 71% and 74%, respectively.
The majority of the 209 tested chemicals were tumorigens (64%). Somewhat more of the SAL+ chemicals were tumorigenic (74%), compared to the SAL-chemicals (51%). The 90 SAL+ tumorigens were more decisively tumorigenic in the sense that only 12% were in the some evidence category, compared to 34% for the 44 SAL-tumorigens.
Somewhat more of the 209 chemicals were selected for bioassay because of structural resemblance to carcinogens or mutagens (Rationale 2; 47%), compared to those that were tested solely because of widespread use (Rationale 1; 35%). This was not statistically significant at p = 0.05. Comparing Rationales 1 and 2, the SAP group was heavily weighted (2.5:1) toward chemicals with structural resemblance to carcinogens (Rationale 2), while the SALchemicals were heavily weighted (3.2:1) toward those that were selected because of widespread exposure (Rationale 1).
Of the 209 chemicals, there were 36 (17%) that were contact sensitizers for humans. Table 6 summarizes the data from the 36 contact sensitizing chemicals for the same parameters as those shown in Table 5 for the total sample of 209 chemicals. About two-thirds (63%) of the contact sensitizers were in the SAL-category. This differs from the bioassay population as a whole, in which 42% were SAL-. The same high proportion of both SAL-and SAL+ chemicals (80%) were CHO+ as in the entire bioassay sample (72%). As with the total sample of bioassay chemicals, the majority of the SAL+ sensitizers (55%) were tested because of structural resemblance to carcinogens and mutagens (Rationale 2), and most (80%) of the SALsensitizers were bioassayed because of widespread usage (Rationale 1). About half (54%) of the contact sensitizers were tumorigenic; a larger proportion of the SAL+ contact sensitizers were tumorigenic (77%) compared to the SAL sensitizers (41%). A larger proportion (44%) of the SAL-tumorigens were in the some evidence category compared with 20% in the SAL+ sensitizer carcinogen group. Thus the contact sensitizers differed from the total sample of bioassay chemicals in only two respects: the rationale for selection was different and there was a greater proportion of SAL-chemicals among the contact sensitizers. Table 7 shows the frequency distribution of the tumor scores, i.e., the number of organs in which tumors were induced, as described above according to the Ames assay, for the total NTP sample and for contact sensitizers alone, without regard to the route of administration. The frequency distributions were biased toward the low tumor scores and were analyzed as log distributions. In the total NTP sample, the SAL+ chemicals had about twice the tumor score as the SALchemicals, with a geometric mean and geometric standard deviation of 2.1 ± 2.3 and 0.9 ± 2.0, respectively. This was statistically, significant (p20.0001). The SAL+ contact sensitizers also had a higher geometric mean tumor score than the SAL-contact sensitizers, 1.3 ± 1.9 compared to 0.8 ± 2.1, but the difference was not statistically significant (p = 0.3). There were no blockbuster chemicals in any group except the SAL+, CHO+ group, in which 1,2-dibromoethane, 2,3-dibromo-1-propanol, glycidyl, and 1,2,3-trichloropropane had tumor scores of 15, 23, 25, and 19, respectively. There were a few SAL+ contact sensitizers that had substantial tumor scores such as coumarin (9) , and 2,4-toluene diisocyanate (9) . Among the SAL-contact sensitizers, only N-methylolacrylamide and 2-mercaptobenzothiazole had substantial tumor scores of 7 and 6, respectively.
As indicated above, the characterization of tumor responses as tumor scores was a measure of the pervasiveness of the tumorigenic action across species, organs, and sex. Potency was characterized, with respect to genotoxicity, on the basis of the dosage (milligrams per kilogram per day) estimated to produce a 50% tumor incidence (TD50) using published values (10) for many of the same chemicals that were included in this analysis but necessarily excluding those which were nontumorigenic. There were no statistically significant differences according to genotoxicity; this could hardly be otherwise because the range of potencies was enormous, as reflected by the extremes where the difference was a factor of 109.
There appeared to be a difference, according to genotoxicity, in the organs in which tumors were induced in both the total NTP sample and the contact sensitizers. The organs were stratified according to The organs where tumors derived, at least partly, from lining epithelium included the mucosa of the bladder, the bronchial and nasal mucosae, the lining of the gastrointestinal tract from the mouth through the intestines, the skin and adnexal structures, the sebaceous gland of the ear canal (Zymbal gland), and the epithelia of the breast and clitoral and preputial glands. The tumor response in a given organ in one species compared to another, the background tumor rate was generally higher in the organ of the species with the higher tumor response. Table 9 compares the background tumor rates in various organs of rats and mice (11) bincludes mammary, clitoral, and preputial glands. clncludes thyroid, adrenal, and pituitary. dThe aggregate percentage is less than 100% because miscellaneous organs in which small numbers of tumors occurred were not included in the analysis.
Discussion
Summarizing the above findings, it can be said that of the 209 bioassayed chemicals included in this analysis, 36 were known to be human contact sensitizers (17%). The contact sensitizers differed from the NTP bioassay group as a whole in that a larger proportion were nongenotoxic, which was probably related to the fact that fewer of them were selected for bioassay on the basis of their structural resemblance to known carcinogens, in contrast to widespread usage. When sorted for genotoxicity, the Environmental Health Perspectives * Volume 105, Number 9, September 1997 contact sensitizers had about the same characteristics as the total population of bioassayed chemicals in the following respects: 1) roughly the same proportion were tumorigenic; 2) proportionately more of the SAL+ chemicals were tumorigenic than those that were SAL-; 3) the SALtumorigens had a greater proportion of less decisive (some evidence) tumor responses than the SAP tumorigens; 4) the tumor scores were greater in the SAL+ chemicals than in the SAL-chemicals; and 5) the SAL-chemicals had proportionately more parenchymal tumors (renal, liver, and endocrine tumors and leukemia) than the SAL+ chemicals, whereas the latter produced relatively more epithelial tumors [bladder, gastrointestinal, skin and zymbal gland, breast, clitoral and preputial glands, and respiratory tumors (nose and lung)].
Most of the chemicals were CHO+ regardless of whether they were SAL+ or SAL-or whether they were carcinogens. This may reflect the possibility that the underlying reason why all of the chemicals were chosen for bioassay, regardless of the specific rationale, was because they were highly reactive as intermediates in chemical synthesis or as reactive finished products; perhaps highly reactive chemicals tend to react with protein. This might mean that many of the NTP bioassay chemicals are contact sensitizers. If so, a comparison of the characteristics of the contact sensitizers to the total group of bioassay chemicals has the limitation that some substantial fraction of the chemicals that were not known to be contact sensitizers may actually be so.
The concentration of contact sensitizers in the SAL-CHO+ category is unexplained. The status of a chemical as CHO+ or CHO-did not consistently affect tumorigenicity. The SAL-CHO-group was anomalous because of its high proportion of tumorigens.
The similarity of the characteristics of the contact sensitizers with those of the entire NTP sample raises the issue of whether contact sensitization might be unrelated to tumorigenicity, i.e., selecting for contact sensitizers constitutes a random sample of bioassay chemicals. However, contact sensitizers were not a random sample because of the differences in the rationale for selection; the properties of the contact sensitizers and the total NTP sample only matched when the two groups were compared on the basis of mutagenicity.
The connection between tumorigens and contact sensitizers relates to the ability of both classes of chemicals to interact with protein. ACD, caused by SAL-contact sensitizers, might be a useful biomarker for identifying nongenotoxic tumor promoters. SAL' contact sensitizers would be expected to be both tumor promoters and initiators. A possible common denominator between contact sensitization and tumor promotion might be the induction of inflammation. ACD is an inflammatory reaction caused by a complex immune response set off by the chemical interaction of the sensitizer, the haptene, with skin proteins. The resultant complex, the antigen, ultimately sensitizes T lymphocytes, which are drawn to the site of skin exposure where they induce a Type IV cell-mediated inflammatory reaction. Contact sensitization also occurs in animals, and the inflammatory reaction is indistinguishable from inflammation produced by skin tumor promoters. Inflammation is a characteristic of many tumor promoters (13, 14) . Mechanistically, the connection between inflammation and tumor promotion is thought to involve the production of free radicals (15, 16 (1) , and 2,4-dinitro-1-fluorobenzene (1) for mouse skin and butyl hydroxytoluene for rat liver (18) . The ability of tumorigens to induce inflammation may be the basis for the promoting component of their action; whether this is due to an immune or irritant reaction is not known (19) .
The action of contact sensitizing tumorigens may be stimulated by the induction of humoral immunity. For example, mice injected with rabbit benzo(a)pyrene (BaP) antibodies show a much enhanced skin tumor response to BaP applied dermally (20) . Moreover, there is evidence that transplanted malignant cells grow faster in a host that had been previously immunized against them (21) .
We examined the issue of whether contact sensitizers are tumor promoters as a consequence of their immunological effects in a previous study that used a well-known contact sensitizer and tumor promoter (22,23), 1-fluoro 2,4-dinitrobenzene (DNFB), in Tg.AC mouse skin. This transgenic mouse is tumor initiated by the presence of a mutated ras oncogene and is therefore a model for skin tumor promotion (24) . The skin application of DNFB produced the typical promotional response of squamous papillomas, with an associated dermal inflammatory reaction. However, the immune-depressing corticosteroid fluocinolone acetonide applied locally did not reduce either the inflammation or the tumor response, suggesting that some component of cytotoxicity, not immunogenicity, caused both the inflammation and the tumor promotion, namely, that contact sensitization and tumor promotion may be independent responses to electrophilic chemicals (1) . Figure 1 illustrates some of the interrelationships that might exist between electrophilicity, macromolecular adduction, and various biological responses. Two linkages of electrophilicity are shown: DNA and protein adduction. DNA adduction is linked to mutagenicity and thus to tumor initiation and progression. Protein adduction is shown to have a four-way linkage to cell-mediated immunity (contact sensitization), humoral immunity, cytotoxicity, and indirectly to mutagenicity (e.g., possibly by interference with DNA repair and chromosomal segregation). The immune and cytotoxic responses are linked with inflammation and thus with tumor promotion. Promotion of atherosclerotic lesions is included on the basis that polycyclic aromatic hydrocarbon carcinogens like benzo(a)pyrene and 7,12 dimethylbenz(a)anthracene promote the development of aortic atheromata in chickens (25) ; this finding was prompted by the evidence that aortic atheromatous plaques in humans have a tumorlike monoclonal origin (26) . The evidence for the existence of some of these linkages is modest. However, Figure 1 does illustrate that the contact sensitizing and carcinogenic properties of electrophilic chemicals could be independent expressions of their common underlying chemical (electrophilic) reactions, i.e., that contact sensitizers are not tumorigens on the basis of their immunogenic effects but rather because of some aspect of their toxicity. It would be useful to know whether the immune response of contact sensitizers enhances tumorigenicity; if so, immunogenically responsive people might be at increased tumorigenic risk.
Carcinogen-induced deletion of proteins, vital to growth control, was a prominent theory of cancer that stemmed from early work on protein binding in the liver by p-aminoazobenzene, a chemical that, interestingly, is a contact sensitizer (27) . This theory was overshadowed by the discovery of carcinogen-induced genotoxicity and was relegated to an epigenetic role (3) . Perhaps the epigenetic role of electrophileinduced protein damage is promotion of genetic damage.
A combination of the Ames assay for mutagenicity and an assay for contact sensitization, as a screening tool, might be an improvement in the detection efficiency for environmental tumorigens over that from the Ames assay alone because it would help to uncover rodent tumorigens among the SAL-chemicals. This is seen in an analysis of the Rationale 1 chemicals (widespread use without structural resemblance to known carcinogens), the group that is probably the most relevant to the generality of chemicals in the environment. Of the 73 Rationale 1 chemicals, 23 were SAL' (32%); of these, 15 were tumorigens on bioassay (65%) with an overall tumorigenic detection efficiency of 21% (15/73). Of the remaining 50 chemicals that were SAL-, 16 (32%) were contact sensitizers; of these, 7 (44%) were tumorigenic on bioassay for an overall detection efficiency of 14% (7/50). Thus, in this illustration, if a contact sensitization bioassay followed the Ames test, the yield of rodent tumorigens among the 73 Category I chemicals would rise from 15 to 22, a 43% increase because of the inclusion of SAL-chemicals. An evaluation of false negatives cannot be made because the unknown proportion of chemicals that are not recognized as contact sensitizers, but might be if they were tested. There would be little or no advantage to combining the Ames assay with an assay for contact sensitization when the Ames test is positive because there is a statistically insignificant increase in the efficiency of detecting tumorigens; i.e., 77% compared to 65%.
The 3% of Merck Index chemicals that are contact sensitizers contrasts with the 17% of chemicals in the NTP bioassay series. The Merck chemicals were selected because they were biologically related, and the NTP chemicals were mostly reactive industrial intermediates or compounds in commercial use because of their pesticidal toxicity. The proportion of the 60,000 chemicals in commercial use (28) that are contact sensitizers ranges from 3% to 17%.
An average of 10%, for purposes of estimation, yields perhaps 6,000 contact sensitizers in commercial use. If, as in this analysis of the NTP experience, about half of the contact sensitizers are tumorigenic in the rodent bioassay, there would be about 3,000 chemicals in commerce that would have to be taken seriously as possible tumorigens.
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Furthermore, it is likely that only a fraction of contact sensitizers have been identified because it is notoriously difficult to specify a causal agent in most cases of ACD. If contact sensitizers induce tumors because of protein interaction, independent of immunogenicity, then the contact sensitization per se might underestimate tumorigenicity because only some protein adducts induce an immunogenic response.
The finding that contact sensitization might be a useful marker for nongenotoxic tumorigens is necessarily preliminary, because the identification of contact sensitizers in the NTP bioassay series was a matter of happenstance. A more systematic evaluation of the immune response to these NTP chemicals might provide a better definition of the utility of contact sensitization as a screen for potential nongenotoxic environmental tumorigens. An improved understanding of the nature of the macromolecular interactions of contact sensitizers might elucidate why some of these electrophiles are protein interactive but nongenotoxic; also, a better understanding of the chemical mechanisms might lead to an in vitro test that is more relevant to tumorigenesis than contact sensitization.
